Mandate

Vinge represented affiliates of American Industrial Partners in entering into an agreement to acquire Veoneer’s Restraint Control Systems business from SSW Partners

Veoneer is the world leader in automotive electronic restraint control systems and has sold more than 1 billion electronic control units and crash sensors. Veoneer’s scalable, best-in-class restraint control systems are saving lives by mitigating the effects of car crashes. In 2023, the company’s products are part of more than 40 scheduled vehicle launches. The company has approximately 2,700 employees in 11 countries.

AIP is a middle market private equity firm focused on industrial businesses. The firm manages over $16 billion on behalf of its limited partners and invests in the aerospace and defense, automotive, building products, capital goods, chemicals, industrial services, industrial technology, logistics, metals and mining, transportation and other sectors.

Vinges team consisted of Ulrich Ziche (M&A), Daniel Wendelson, Hilda Ivarsson, Alva Chambert (EU, Competition and Regulatory), Simon Söderholm (Employment & Benefits) and Marcus Eklund (Investigations & International Disputes).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025